SAN DIEGO, Calif.--(BUSINESS WIRE)--The 2017 BIO International Convention (BIO 2017), the world’s largest gathering of the biotechnology industry, entered the second day of compelling, immersive programming united under the theme of “Breakthrough.” Hosted by the Biotechnology Innovation Organization (BIO), BIO 2017 will run through Thursday, June 22 at the San Diego Convention Center.
A keynote session with David Cameron, Former Prime Minster of the United Kingdom, leads BIO 2017’s second day of programming, which will also include several fireside chats and super sessions.
Tuesday, June 20 Highlights Include:
Cameron, Former Prime Minister of the United Kingdom
David Cameron, will be interviewed by BIO President & CEO, Jim Greenwood for a worldly discussion on the rapidly changing political landscape both in the United States and abroad. BIO will also recognize BioGENEius student award winners and introduce BIO’s new Board Chair, John Maraganore, Ph.D.
9:00 – 10:30 a.m. | Ballroom 20, Upper Level
- PLEASE NOTE: Keynotes are open to Convention Access and Partnering Attendees. Seating is first-come, first-served.
Fireside Chat: David
Hung, MD, Chief Executive Officer, Axovant Sciences
Join us for a fireside chat with David T. Hung, MD, Chief Executive Officer at Axovant Sciences. Dr. Hung has served as the Chief Executive Officer and as a member of the Board since April 2017.
11:00 a.m. – 12:00 p.m. | Room 6A, Upper Level
Super Session: Our
Common Goal: Ensuring Access and Affordability of Innovative Medicines
Join us for a wide-ranging, lively conversation with healthcare industry veterans as they debate and discuss the central question facing our industry: How do we ensure access and affordability of innovative medicines? The panelists will determine where there is common ground and where the debate is heading in the coming years. The focus will be on solutions, on finding areas of agreement and where fresh and innovative thinking can move us past the roadblocks of past debates. Get the panelists’ unique insights and an unvarnished look at the most pressing issues we face from leaders who have been on the frontlines of healthcare innovation for decades.
12:15 – 1:30 p.m. | Room 6A, Upper Level
Super Session: Dealmakers’
Intentions: 2017 Market Outlook
While the past year has seen a fading in the IPO market, the volume of deal flow and valuations for M&A remain high. Many of the largest industry members have strong cash positions, and most analysts continue to expect pipeline enhancement via acquisition. As political forecasts suggest high potential for tax reform and other changes in how international deals might be reviewed, there are multiple ways 2017 could be a great year or a terrible year for biopharma M&A. This session will talk through the likely and extreme scenarios, as well as provide insight on what signs to watch for from Washington and Wall St. along the way. Session attendees will hear updated findings from two unique, forward-looking measures of deal-making in the industry: the inVentiv Health Consulting Dealmakers' Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives and business development professionals, Dealmakers' Intentions provides insight into what will likely drive the industry's partnering and M&A efforts moving forward and the implications for deal-making over the next year or more. Now in its ninth year, analysis will include year-over-year trends, deal metrics and broader M&A data. Additionally, a highly distinguished panel of deal-makers will explore the impact these market forces will have on pharmaceutical and biotech companies as they strive to make the next big deal.
12:15 – 1:30 p.m. | Room 6B, Upper Level
Press Conference: The
Economic Contribution of University/Nonprofit Inventions in the United
Learn about the economic impact of biotech innovations from academic institutions (BIO/AUTM survey release).
1:30 – 2:30 p.m. | Press Conference Room, 32B Upper Level
Fireside Chat: Daniel
Skovronsky, Senior Vice President, Clinical and Product Development at
Eli Lilly and Company and Chairman, Avid Radiopharmaceuticals
Join us for a fireside chat with Daniel M. Skovronsky, M.D., Ph.D., Senior Vice President, Clinical and Product Development at Eli Lilly and Company, with responsibility for developing the Lilly pipeline of molecules and speeding innovative medicines to patients.
4:00 – 5:00 p.m. | Room 5B, Upper Level
Wednesday, June 21 Highlights Include:
Romney, Wife of Mitt Romney, Patient Advocate and Best-Selling Author
Ann Romney will take the stage to discuss her experience living with Multiple Sclerosis and share personal stories of trials and tribulations as a patient. With remarkable stories and insights that will touch all audiences, her valued perspective on her life in and out of the political spotlight is engaging and informative. BIO President & CEO, Jim Greenwood, will also give his annual “State of the Biotechnology Industry” address, discussing the latest challenges, opportunities and breakthroughs facing the biotechnology industry.
9:00 – 10:30 a.m. | Ballroom 20, Upper Level
- PLEASE NOTE: Keynotes are open to Convention Access and Partnering Attendees. Seating is first-come, first-served
Fireside Chat: Francis
deSouza, President & CEO, Illumina
Join us for a fireside chat with Francis deSouza, President & CEO of Illumina. Francis deSouza was appointed President & CEO of Illumina in 2016 and is responsible for directing all aspects of company strategy, planning, and operations. He initially joined the company as President in 2013, and led Illumina’s business units and core functions responsible for envisioning, developing and producing the company’s products.
11:00 a.m. – 12:00 p.m. | Room 5B, Upper Level
Super Session: The
Trade and Investment Policies of the Trump Administration
After 6 months in office, what is the outlook and implications for the biotechnology industry for the Trump Administration’s trade and investment policies? This panel will focus on the North American Free Trade Agreement (NAFTA), Europe/UK, China and other notable areas.
12:15 – 1:30 p.m. | Room 6A, Upper Level
Fireside Chat: Kathleen
“Kate” Rubins, PhD, Astronaut, NASA
Wednesday, June 21
Join us for a fireside chat with Kate Rubins, NASA Astronaut. Kate was selected by NASA in 2009 and completed her first spaceflight on Expedition 48/49, where she became the first person to sequence DNA in space. She spent 115 days in space and conducted two spacewalks.
1:45 – 2:45 p.m. | Room 5B, Upper Level
Fireside Chat: Understanding
the Patient Voice: Three Unique Perspectives on Healthcare
Wednesday, June 21
The role of the patient has evolved dramatically over the past decade. Not only are patients increasingly more involved in their healthcare decision making, they are also passionate advocates who work tirelessly to advance drug development research and development and secure a public policy environment that is patient-centric. Join a discussion with three patient advocates as they discuss their journeys to diagnosis and their viewpoints on our healthcare system. They will share their perspectives on what it means to be a patient and how they are advocating in their own unique ways to achieve a common goal: bringing new treatments to patients.
3:00 – 4:15 p.m. | Room 5B, Upper Level
Emerging Opportunities in Global Health: The
African Cancer Crisis
In 2015, the annual deaths in Africa due to cancer surpassed those due to malaria. For many in the developed world, cancer is a life-changing disease – but it is no longer a death sentence. The same cannot be said for most cancer patients in Africa. Cancer is a growing crisis on the African continent. In the past two decades, cancer incidence in Africa has doubled and deaths due to cancer have increased 62%. This is in stark contrast to the United States, where cancer incidence has increased 60% but deaths have increased only 21%. This African cancer epidemic is anything but straightforward, yet it must be prioritized. This panel session will explore the current state of cancer in Africa and describe how pharmaceutical and biotechnology companies can engage and begin to tackle this crisis before it’s too late. The panel will describe Africa’s cancer burden and the realities of cancer diagnosis and treatment on the continent. The discussion will include the perspective of government and industry in setting priorities, strategies, and access to medicines. Finally, the panel will discuss a new program launched by BIO Ventures for Global Health (BVGH) – the African Access Initiative (AAI) – with the aim of improving cancer patient management and creating new business models to ensure affordable, sustainable access to essential cancer technologies and therapeutics in Africa.
3:00 – 4:30 p.m. | Room 27AB, Upper Level
Media registration is open on Monday from 7:00 a.m. – 5:00 p.m. and on Tuesday from 6:30 a.m. – 3:00 p.m. at the San Diego Convention Center. The majority of attendees, 70 percent, are c-level executives. They split evenly from large companies of 500 or more employees and small companies of 50 employees or less.
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. The Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/ for the most up-to-date program and speaker information.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
BIO World Congress
on Industrial Biotechnology
July 23-26, 2017
BIO Patient and Health
The Mayflower Hotel, Washington, DC
October 2-3, 2017
BIO Investor Forum
October 17-18, 2017